SRBD1 facilitates chromosome segregation by promoting topoisomerase IIα localization to mitotic chromosomes
Accurate sister chromatid segregation requires remodeling chromosome architecture, decatenation, and attachment to the mitotic spindle. Some of these events are initiated during S-phase, but they accelerate and conclude during mitosis. Here we describe SRBD1 as a histone and nucleic acid binding protein that prevents DNA damage in interphase cells, localizes to nascent DNA during replication and the chromosome scaffold in mitosis, and is required for chromosome segregation. SRBD1 inactivation causes micronuclei, chromatin bridges, and cell death. Inactivating SRBD1 immediately prior to mitotic entry causes anaphase failure, with a reduction in topoisomerase IIα localization to mitotic chromosomes and defects in properly condensing and decatenating chromosomes. In contrast, SRBD1 is not required to complete cell division after chromosomes are condensed. Strikingly, depleting condensin II reduces the severity of the anaphase defects in SRBD1-deficient cells by restoring topoisomerase IIα localization. Thus, SRBD1 is an essential genome maintenance protein required for mitotic chromosome organization and segregation.
Authors
- Masato T. Kanemaki (ORCID: https://orcid.org/0000-0002-7657-1649)
- Yuki Hatoyama (ORCID: https://orcid.org/0000-0001-5554-8311)
- Courtney A. Lovejoy (ORCID: https://orcid.org/0000-0001-9178-5226)
- Rahul Bhowmick (ORCID: https://orcid.org/0000-0002-5412-1209)
- Runxiang Zhao
- Sarah R. Wessel
- David Cortez (ORCID: https://orcid.org/0000-0003-0154-140X)
Institutions
- National Institute of Genetics (JP)
- The Graduate University for Advanced Studies, SOKENDAI (JP)
- Vanderbilt University (US)
- Research Organization of Information and Systems (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-02-16
- DOI
- https://doi.org/10.1038/s41467-025-56911-w
- Citations
- 3
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Breast Cancer Research Foundation
- Vanderbilt University
- Vanderbilt-Ingram Cancer Center
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences